Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 76 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2015', provides an overview of the Peripheral Neuropathy (Sensory Neuropathy)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Peripheral Neuropathy (Sensory Neuropathy)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Peripheral Neuropathy (Sensory Neuropathy) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Peripheral Neuropathy (Sensory Neuropathy) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Peripheral Neuropathy (Sensory Neuropathy) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Peripheral Neuropathy (Sensory Neuropathy) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Peripheral Neuropathy (Sensory Neuropathy) Overview 8
Therapeutics Development 9
Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) - Overview 9
Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis 10
Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics under Development by Companies 11
Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics under Investigation by Universities/Institutes 13
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Peripheral Neuropathy (Sensory Neuropathy) - Products under Development by Companies 17
Peripheral Neuropathy (Sensory Neuropathy) - Products under Investigation by Universities/Institutes 18
Peripheral Neuropathy (Sensory Neuropathy) - Companies Involved in Therapeutics Development 19
Acorda Therapeutics, Inc. 19
aTyr Pharma, Inc. 20
GeNeuro SA 21
INSYS Therapeutics, Inc. 22
Mitsubishi Tanabe Pharma Corporation 23
Neuren Pharmaceuticals Limited 24
Pfizer Inc. 25
RegeneRx Biopharmaceuticals, Inc. 26
Takeda Pharmaceutical Company Limited 27
Teijin Pharma Limited 28
Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
cannabidiol - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
fingolimod hydrochloride - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
GL-2045 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
immune globulin (human) - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
immune globulin (human) - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Monoclonal Antibody for CIDP - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
NNZ-2591 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
NP-1998 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
NRP-2945 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Peptides for Neuropathic Pain and Peripheral Neuropathy - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Proteins for Inflammation, Hematological, Metabolic, Oncology, Neurodegenerative and Cardiovascular Disorder - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
RGN-352 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Small Molecules to Inhibit Cysteine Protease and Caspases for Oncology, Immunology, Infectious and CNS Disorders - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Synthetic Peptides for Peripheral Neuropathy - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Peripheral Neuropathy (Sensory Neuropathy) - Recent Pipeline Updates 62
Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects 72
Peripheral Neuropathy (Sensory Neuropathy) - Discontinued Products 73
Peripheral Neuropathy (Sensory Neuropathy) - Product Development Milestones 74
Featured News & Press Releases 74
Jul 12, 2013: Neuren Receives Notice of Allowance for New Patent 74
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 76
Disclaimer 76

List of Tables
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H1 2015 9
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Investigation by Universities/Institutes, H1 2015 18
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Acorda Therapeutics, Inc., H1 2015 19
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by aTyr Pharma, Inc., H1 2015 20
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by GeNeuro SA, H1 2015 21
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by INSYS Therapeutics, Inc., H1 2015 22
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 23
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Neuren Pharmaceuticals Limited, H1 2015 24
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Pfizer Inc., H1 2015 25
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2015 26
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 27
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Teijin Pharma Limited, H1 2015 28
Assessment by Monotherapy Products, H1 2015 29
Number of Products by Stage and Target, H1 2015 31
Number of Products by Stage and Mechanism of Action, H1 2015 33
Number of Products by Stage and Route of Administration, H1 2015 35
Number of Products by Stage and Molecule Type, H1 2015 37
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics - Recent Pipeline Updates, H1 2015 62
Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects, H1 2015 72
Peripheral Neuropathy (Sensory Neuropathy) - Discontinued Products, H1 2015 73